The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Novel quadruplet and triplet front-line options for early R/R multiple myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how novel triplet and quadruplet regimens have transformed front-line treatment for early relapsed/refractory (R/R) multiple myeloma (MM). The BENEFIT (NCT04751877) and IMROZ (NCT03319667) trials support using these regimens even in elderly patients. Dr Usmani also notes the need to consider the efficacy of regimens incorporating anti-CD38 antibodies in patients previously exposed to these agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Abbvie, Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda. Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Gracell Therapeutics, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
